Synopsis
Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bentelan
2. Betamethason Sodium Phosphate
3. Betamethasone 21-phosphate
4. Betamethasone Disodium Phosphate
5. Betamethasone Disodium Phosphate, (11beta)-isomer
6. Betamethasone Phosphate
7. Betamethasone Sodium Phosphate, (11beta,16beta)-isomer
8. Betnesol
9. Celestone Phosphate
10. Rinderone
1. 151-73-5
2. Bentelan
3. Betamethasone 21-phosphate Disodium Salt
4. Betamethasone 21-phosphate Disodium
5. Betamethasone Disodium Phosphate
6. Betamethazone Disodium Phosphate
7. Betamethasone 21-disodium Phosphate
8. Beta-methasone Sodium Phosphate
9. Betamethasone 21-phosphate Sodium Salt
10. 7bk02scl3w
11. Chebi:3078
12. 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-(disodium Phosphate)
13. Betamethasone Sodium Phosphate, Usp
14. Disodium Betamethasone 21-phosphate
15. Beta-methasone Phosphate
16. Celestone Phosphate Injection
17. Nsc 90616
18. Disodium;[2-[(8s,9r,10s,11s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] Phosphate
19. Sodium 2-((8s,9r,10s,11s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl Phosphate
20. Nsc-90616
21. Beta-methasone, Disodium Phosphate
22. Einecs 205-797-0
23. Unii-7bk02scl3w
24. Beta-methasone Disodium Phosphate
25. Mfcd00200361
26. Betamethasone Sodium Phosphate [usp:jan]
27. Betamethasonesodiumphosphate
28. Schembl8418
29. Dsstox_cid_27137
30. Dsstox_rid_82144
31. Dsstox_gsid_47137
32. Chembl1200762
33. Dtxsid8047137
34. Tox21_302467
35. Akos015896371
36. Ac-2162
37. Ncgc00256717-01
38. As-62442
39. Cas-151-73-5
40. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, Disodium Salt, (11.beta.,16.beta.)-
41. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, Disodium Salt, (11beta,16beta)-
42. Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-, 21-(dihydrogen Phosphate), Disodium Salt
43. Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-16beta-methyl-, 21-(dihydrogen Phosphate), Disodium Salt
44. Betamethasone Sodium Phosphate (jp17/usp)
45. Betamethasone Sodium Phosphate [jan]
46. B4110
47. Betamethasone 21-phosphate Disodium, >=97%
48. Betamethasone Sodium Phosphate [mart.]
49. Betamethasone Sodium Phosphate [vandf]
50. Betamethasone Sodium Phosphate [usp-rs]
51. Betamethasone Sodium Phosphate [who-dd]
52. D00972
53. Betamethasone Sodium Phosphate [green Book]
54. Betamethasone Sodium Phosphate [ep Impurity]
55. Betamethasone Sodium Phosphate [ep Monograph]
56. Betamethasone Sodium Phosphate [orange Book]
57. J-008838
58. Betamethasone Sodium Phosphate [usp Monograph]
59. Q27105936
60. Betamethasone Sodium Phosphate Component Of Celestone Soluspan
61. Celestone Soluspan Component Betamethasone Sodium Phosphate
62. Betamethasone Sodium Phosphate, European Pharmacopoeia (ep) Reference Standard
63. Betamethasone Sodium Phosphate, United States Pharmacopeia (usp) Reference Standard
64. 9-fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 21-(disodium Phosphate)
65. Disodium 9-fluoro-11beta,17-dihydroxy-16beta-methyl-3,20-dioxopregna-1,4-dien-21-yl Phosphate
| Molecular Weight | 516.4 g/mol |
|---|---|
| Molecular Formula | C22H28FNa2O8P |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 3 |
| Exact Mass | 516.13012157 g/mol |
| Monoisotopic Mass | 516.13012157 g/mol |
| Topological Polar Surface Area | 147 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 962 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Solubilizers
Parenteral
Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
97
PharmaCompass offers a list of Betamethasone Sodium Phosphate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Betamethasone Sodium Phosphate manufacturer or Betamethasone Sodium Phosphate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Betamethasone Sodium Phosphate manufacturer or Betamethasone Sodium Phosphate supplier.
PharmaCompass also assists you with knowing the Betamethasone Sodium Phosphate API Price utilized in the formulation of products. Betamethasone Sodium Phosphate API Price is not always fixed or binding as the Betamethasone Sodium Phosphate Price is obtained through a variety of data sources. The Betamethasone Sodium Phosphate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CELESTONE SOLUSPAN-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CELESTONE SOLUSPAN-1, including repackagers and relabelers. The FDA regulates CELESTONE SOLUSPAN-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CELESTONE SOLUSPAN-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CELESTONE SOLUSPAN-1 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CELESTONE SOLUSPAN-1 supplier is an individual or a company that provides CELESTONE SOLUSPAN-1 active pharmaceutical ingredient (API) or CELESTONE SOLUSPAN-1 finished formulations upon request. The CELESTONE SOLUSPAN-1 suppliers may include CELESTONE SOLUSPAN-1 API manufacturers, exporters, distributors and traders.
click here to find a list of CELESTONE SOLUSPAN-1 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CELESTONE SOLUSPAN-1 DMF (Drug Master File) is a document detailing the whole manufacturing process of CELESTONE SOLUSPAN-1 active pharmaceutical ingredient (API) in detail. Different forms of CELESTONE SOLUSPAN-1 DMFs exist exist since differing nations have different regulations, such as CELESTONE SOLUSPAN-1 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CELESTONE SOLUSPAN-1 DMF submitted to regulatory agencies in the US is known as a USDMF. CELESTONE SOLUSPAN-1 USDMF includes data on CELESTONE SOLUSPAN-1's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CELESTONE SOLUSPAN-1 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CELESTONE SOLUSPAN-1 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The CELESTONE SOLUSPAN-1 Drug Master File in Japan (CELESTONE SOLUSPAN-1 JDMF) empowers CELESTONE SOLUSPAN-1 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the CELESTONE SOLUSPAN-1 JDMF during the approval evaluation for pharmaceutical products. At the time of CELESTONE SOLUSPAN-1 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of CELESTONE SOLUSPAN-1 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a CELESTONE SOLUSPAN-1 Drug Master File in Korea (CELESTONE SOLUSPAN-1 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of CELESTONE SOLUSPAN-1. The MFDS reviews the CELESTONE SOLUSPAN-1 KDMF as part of the drug registration process and uses the information provided in the CELESTONE SOLUSPAN-1 KDMF to evaluate the safety and efficacy of the drug.
After submitting a CELESTONE SOLUSPAN-1 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their CELESTONE SOLUSPAN-1 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of CELESTONE SOLUSPAN-1 suppliers with KDMF on PharmaCompass.
A CELESTONE SOLUSPAN-1 CEP of the European Pharmacopoeia monograph is often referred to as a CELESTONE SOLUSPAN-1 Certificate of Suitability (COS). The purpose of a CELESTONE SOLUSPAN-1 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of CELESTONE SOLUSPAN-1 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of CELESTONE SOLUSPAN-1 to their clients by showing that a CELESTONE SOLUSPAN-1 CEP has been issued for it. The manufacturer submits a CELESTONE SOLUSPAN-1 CEP (COS) as part of the market authorization procedure, and it takes on the role of a CELESTONE SOLUSPAN-1 CEP holder for the record. Additionally, the data presented in the CELESTONE SOLUSPAN-1 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the CELESTONE SOLUSPAN-1 DMF.
A CELESTONE SOLUSPAN-1 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. CELESTONE SOLUSPAN-1 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of CELESTONE SOLUSPAN-1 suppliers with CEP (COS) on PharmaCompass.
A CELESTONE SOLUSPAN-1 written confirmation (CELESTONE SOLUSPAN-1 WC) is an official document issued by a regulatory agency to a CELESTONE SOLUSPAN-1 manufacturer, verifying that the manufacturing facility of a CELESTONE SOLUSPAN-1 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting CELESTONE SOLUSPAN-1 APIs or CELESTONE SOLUSPAN-1 finished pharmaceutical products to another nation, regulatory agencies frequently require a CELESTONE SOLUSPAN-1 WC (written confirmation) as part of the regulatory process.
click here to find a list of CELESTONE SOLUSPAN-1 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CELESTONE SOLUSPAN-1 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CELESTONE SOLUSPAN-1 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CELESTONE SOLUSPAN-1 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CELESTONE SOLUSPAN-1 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CELESTONE SOLUSPAN-1 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CELESTONE SOLUSPAN-1 suppliers with NDC on PharmaCompass.
CELESTONE SOLUSPAN-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CELESTONE SOLUSPAN-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CELESTONE SOLUSPAN-1 GMP manufacturer or CELESTONE SOLUSPAN-1 GMP API supplier for your needs.
A CELESTONE SOLUSPAN-1 CoA (Certificate of Analysis) is a formal document that attests to CELESTONE SOLUSPAN-1's compliance with CELESTONE SOLUSPAN-1 specifications and serves as a tool for batch-level quality control.
CELESTONE SOLUSPAN-1 CoA mostly includes findings from lab analyses of a specific batch. For each CELESTONE SOLUSPAN-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CELESTONE SOLUSPAN-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (CELESTONE SOLUSPAN-1 EP), CELESTONE SOLUSPAN-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CELESTONE SOLUSPAN-1 USP).
